Results suggest ABBV-295 could expand the next generation of obesity drugs and deepen the connection between metabolic health and longevity.
Various biotech giants have produced and released obesity treatments that have continued to intensify over the past few years, with blockbuster drugs transforming how doctors and investors think about metabolic health. Now a new contender is emerging from a partnership between Danish biotech Gubra and pharmaceutical giant AbbVie.
Early clinical results released this week suggest their experimental therapy, ABBV-295, could produce meaningful weight loss in a relatively short time frame [1]. In a Phase 1 multiple ascending dose trial, participants receiving the drug lost between 7.75% and 9.79% of their body weight after about three months of treatment, depending on the dose. By contrast, those receiving a placebo saw almost no change.
For an early-stage study, it is striking. Equally important, researchers reported that the drug was generally well-tolerated, with no serious adverse events recorded.
“We are very encouraged by these clinical results. Obesity continues to be a growing global health challenge, with a well-recognized need for novel treatment options,” said Markus Rohrwild, CEO of Gubra.
“These data demonstrate the potential of ABBV-295 to deliver meaningful body weight reduction with a favorable tolerability profile, supporting its differentiated positioning within the evolving obesity treatment landscape.”
To understand why ABBV-295 is drawing attention, it helps to look at how it works. Most of the headline-making obesity drugs today, such as GLP-1 therapies, work by mimicking hormones that regulate appetite and blood sugar. These drugs have proven highly effective, but they all rely on variations of the same biological pathway.
ABBV-295 takes a different approach. The therapy is designed to mimic amylin, a naturally occurring hormone released alongside insulin. Amylin acts as one of the body’s internal “stop eating” signals, telling the brain that the stomach is full while also slowing the rate at which food leaves the stomach. In simple terms, it helps the body recognize satiety earlier.
The body’s appetite system can be viewed as a dashboard of signals telling you when to start and stop eating. GLP-1 drugs act on one set of controls; amylin-based drugs act on another. Researchers believe targeting multiple signals could eventually lead to more balanced and potentially more sustainable weight management. That possibility is one reason scientists are exploring new mechanisms beyond the current wave of incretin-based treatments.
The Phase 1 study evaluated ABBV-295 in adults with an average body mass index below 30, testing several dose levels ranging from 2 mg to 14 mg. Participants received the treatment through injections under the skin.
Researchers also explored different dosing schedules. Some participants received weekly injections, while others transitioned to less frequent dosing – every other week or even monthly – later in the trial.
Across these variations, a consistent pattern emerged: higher doses led to greater weight loss. After 12 weeks of weekly dosing, participants lost an average of 9.79% of their body weight. Those on placebo experienced only around 0.25% change, essentially a statistical standstill.
Side effects were generally manageable. The most commonly reported issues were mild gastrointestinal symptoms, mostly occurring during the first six weeks of treatment.
According to Dr Primal Kaur, a senior vice president at AbbVie, obesity is a multifaceted, chronic condition that significantly impacts patients and healthcare infrastructure. She noted that there is an ongoing need for treatments that are both effective and manageable enough for patients to adhere to over the long term.
Moreover, Kaur expressed optimism regarding the preliminary data for ABBV-295, stating that the results showed significant weight reduction and a favorable safety profile.
Longevity.Technology: At first glance, obesity drugs like ABBV-295 might appear to belong purely to the realm of metabolic medicine. But increasingly, they are becoming central to discussions about longevity. Excess body weight is strongly linked to many of the diseases that shorten healthy lifespan. Addressing those metabolic risk factors earlier in life can significantly alter long-term health outcomes.
ABBV-295 represents more than cosmetic weight loss. They are an innovation in preventive medicine, where treating metabolic dysfunction today may help delay the onset of chronic disease decades later.
The rapid growth of the obesity therapeutics market was once viewed as a niche category, but it is now a cornerstone of future healthcare. And the next phase of development may not revolve around a single miracle drug. Instead, researchers increasingly envision combination therapies that pair different hormonal pathways (such as GLP-1 and amylin) to amplify benefits while minimizing side effects.
The program itself highlights the scale of opportunity investors see in the space. In March 2025, Gubra and AbbVie entered a licensing agreement that gives AbbVie global rights to develop and commercialize ABBV-295. The deal could deliver up to $1.875 billion to Gubra in milestone payments tied to development progress and commercial performance, as well as royalties on global sales.
Such deals have become increasingly common as large pharmaceutical companies seek a foothold in what analysts expect to become one of the most lucrative drug markets of the coming decade.
ABBV-295 is still an investigational therapy, and much larger clinical trials will be needed before its true potential becomes clear. But early signals like these offer a glimpse into where metabolic medicine may be heading.
If the first generation of obesity drugs helped prove that meaningful weight loss through medication is possible, the next generation may focus on refining the biology behind appetite, metabolism and energy balance.
